Feature

Video

Dr. Shore on what he's most looking forward to at AUA 2024

Author(s):

Urology Times staff
Conference|AUA

Neal D. Shore, MD, shares what he's most looking forward to at this year's American Urological Association Annual Meeting.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Neal D. Shore, MD, shares what he's most looking forward to at this year's American Urological Association (AUA) Annual Meeting, taking place May 3-6 in San Antonio, Texas. Shore is the US chief medical officer of urology/surgical oncology at GenesisCare USA, as well as the director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina.

      Related Videos
      Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
      Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings
      Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Jason Hafron, MD, considers the future for AI in urology
      Jason Hafron, MD, considers the future for AI in urology
      Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
      Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
      Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
      Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
      Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
      Investigators evaluate tamsulosin use in pediatric patients
      Ruchika Talwar, MD, on how urologists can get involved in advocacy
      Ruchika Talwar, MD, on how urologists can get involved in advocacy
      Chad Ellimoottil, MD, on how urologists should approach telehealth in changing policy environment
      Chad Ellimoottil, MD, on how urologists should approach telehealth in changing policy environment
      Related Content
      CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC
      February 20th 2025

      CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC

      Thomas E. Hutson, DO, PharmD
      "The updated results from CLEAR trial confirming that the amount of tumor shrinkage correlates with prognosis through overall survival, PFS, as well as through IMDC prognostic scoring should add further weight to lenvatinib and pembrolizumab being a go-to standard of care in this setting," says Thomas E. Hutson, DO, PharmD.
      Former MLB player Dave Winfield shares lessons from baseball, philanthropy
      November 15th 2024

      Former MLB player Dave Winfield shares lessons from baseball, philanthropy

      Urology Times staff
      In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
      Adding cabozantinib to nivolumab/ipilimumab confers PFS benefit in aRCC
      February 18th 2025

      Adding cabozantinib to nivolumab/ipilimumab confers PFS benefit in aRCC

      Hannah Clarke
      However, the triplet regimen did not lead to an improvement in overall survival.
      blurred photo of a clinic hallway
      May 28th 2023

      2023 AUA highlights in benign urology

      Urology Times staff
      Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
      Urinary bladder cancer | Image Credit: © Matthieu - stock.adobe.com
      February 16th 2025

      Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

      Benjamin P. Saylor
      "The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.
      Human kidney cross section on scientific background | Image Credit: © Crystal light - stock.adobe.com
      February 15th 2025

      Latest LITESPARK-003 data highlight antitumor activity of belzutifan plus cabozantinib

      Benjamin P. Saylor
      ORR was 70% (95% CI, 55-82) in cohort 1 compared with 31% (95% CI, 19-45) in cohort 2.
      © 2025 MJH Life Sciences

      All rights reserved.